Phaseline

Companies › Artios Pharma

Artios Pharma: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ART0380
PARP inhibitor
–Phase 1Advanced CancerJan 2028
ART6043
CHK1 inhibitor
–Phase 1Advanced Solid TumorJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04657068ART0380Phase 1Advanced CancerOncologyJan 2028
NCT05898399ART6043Phase 1Advanced Solid TumorOncologyJun 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.